IRBESARTAN vs NEBIVOLOL

Compare IRBESARTAN (Irbesartan) and NEBIVOLOL (Nebivolol) — clinical data, side effects, and patient experiences.

IRBESARTAN

Irbesartan, Avapro, Avalide · ARB

How it works

ARB agent

Approved for

1 INDICATIONS AND USAGE Irbesartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension

to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events

primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes

an elevated serum creatinine

OralTablet

NEBIVOLOL

Nebivolol, Bystolic · Other

How it works

12.1 Mechanism of Action The mechanism of action of the antihypertensive response of nebivolol has not been definitively established. Possible factors that may be involved include:...

Approved for

1 INDICATIONS AND USAGE Nebivolol is a beta-adrenergic blocking agent indicated for the treatment of hypertension

to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events

primarily strokes and myocardial infarctions.( 1.1 ) 1.1 Hypertension Nebivolol tablets are indicated for the treatment of hypertension

primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes

OralTablet

Quick Comparison

IRBESARTANNEBIVOLOL

Drug Class

ARB

Other

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

IRBESARTAN

Nausea

1-10%

Fatigue

1-10%

Diarrhea

1-10%

Drug Not Working

1-10%

Dizziness

1-10%

Shortness of Breath

1-10%

Headache

1-10%

Falls

1-10%

NEBIVOLOL

Fatigue

1-10%

Diarrhea

1-10%

Shortness of Breath

1-10%

Drug Not Working

1-10%

Nausea

1-10%

Headache

1-10%

Dizziness

1-10%

Weakness

1-10%

FDA Warnings

IRBESARTAN

5 WARNINGS AND PRECAUTIONS Hypotension: Correct volume or salt depletion prior to administration
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death
Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death
, patients with renal artery stenosis, chronic kidney disease, severe heart failure, or volume depletion) may be at particular risk of developing acute renal failure or death on irbesartan tablets

NEBIVOLOL

5 WARNINGS AND PRECAUTIONS Acute exacerbation of coronary artery disease upon cessation of therapy: Do not abruptly discontinue
4 Anesthesia and Major Surgery Because beta-blocker withdrawal has been associated with an increased risk of MI and chest pain, patients already on beta-blockers should generally continue treatment throughout the perioperative period
If β-blocking therapy is withdrawn prior to major surgery, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures
5 Hypoglycemia Beta-blockers may prevent early warning signs of hypoglycemia, such as tachycardia, and increase the risk for severe or prolonged hypoglycemia at any time during treatment, especially in patients with diabetes mellitus or children and patients who are fasting (i

Clinical Trial Data

No head-to-head clinical studies found for IRBESARTAN vs NEBIVOLOL.

IRBESARTAN vs NEBIVOLOL: What You Should Know

Key Differences

IRBESARTAN is a ARB, while NEBIVOLOL belongs to the Other class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles.

Shared Indications

Both medications are approved for to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.

Safety Considerations

IRBESARTAN carries 4 FDA warnings. NEBIVOLOL carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

IRBESARTAN vs SACUBITRIL AND VALSARTAN→IRBESARTAN vs VALSARTAN→IRBESARTAN vs VALSARTAN AND HYDROCHLOROTHIAZIDE→IRBESARTAN vs TELMISARTAN→IRBESARTAN vs TELMISARTAN AND HYDROCHLOROTHIAZIDE→IRBESARTAN vs IRBESARTAN AND HYDROCHLOROTHIAZIDE→

Loading comparison data...

IRBESARTAN vs NEBIVOLOL

Compare IRBESARTAN (Irbesartan) and NEBIVOLOL (Nebivolol) — clinical data, side effects, and patient experiences.

IRBESARTAN

Irbesartan, Avapro, Avalide · ARB

How it works

ARB agent

Approved for

1 INDICATIONS AND USAGE Irbesartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension

to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events

primarily strokes and myocardial infarctions. ( 1.1 ) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes

an elevated serum creatinine

OralTablet

NEBIVOLOL

Nebivolol, Bystolic · Other

How it works

12.1 Mechanism of Action The mechanism of action of the antihypertensive response of nebivolol has not been definitively established. Possible factors that may be involved include:...

Approved for

1 INDICATIONS AND USAGE Nebivolol is a beta-adrenergic blocking agent indicated for the treatment of hypertension

to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events

primarily strokes and myocardial infarctions.( 1.1 ) 1.1 Hypertension Nebivolol tablets are indicated for the treatment of hypertension

primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes

OralTablet

Quick Comparison

IRBESARTANNEBIVOLOL

Drug Class

ARB

Other

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

IRBESARTAN

Nausea

1-10%

Fatigue

1-10%

Diarrhea

1-10%

Drug Not Working

1-10%

Dizziness

1-10%

Shortness of Breath

1-10%

Headache

1-10%

Falls

1-10%

NEBIVOLOL

Fatigue

1-10%

Diarrhea

1-10%

Shortness of Breath

1-10%

Drug Not Working

1-10%

Nausea

1-10%

Headache

1-10%

Dizziness

1-10%

Weakness

1-10%

FDA Warnings

IRBESARTAN

5 WARNINGS AND PRECAUTIONS Hypotension: Correct volume or salt depletion prior to administration
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death
Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death
, patients with renal artery stenosis, chronic kidney disease, severe heart failure, or volume depletion) may be at particular risk of developing acute renal failure or death on irbesartan tablets

NEBIVOLOL

5 WARNINGS AND PRECAUTIONS Acute exacerbation of coronary artery disease upon cessation of therapy: Do not abruptly discontinue
4 Anesthesia and Major Surgery Because beta-blocker withdrawal has been associated with an increased risk of MI and chest pain, patients already on beta-blockers should generally continue treatment throughout the perioperative period
If β-blocking therapy is withdrawn prior to major surgery, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures
5 Hypoglycemia Beta-blockers may prevent early warning signs of hypoglycemia, such as tachycardia, and increase the risk for severe or prolonged hypoglycemia at any time during treatment, especially in patients with diabetes mellitus or children and patients who are fasting (i

Clinical Trial Data

No head-to-head clinical studies found for IRBESARTAN vs NEBIVOLOL.

IRBESARTAN vs NEBIVOLOL: What You Should Know

Key Differences

IRBESARTAN is a ARB, while NEBIVOLOL belongs to the Other class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles.

Shared Indications

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.